catechin has been researched along with Fra(X) Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortés, MJ; Cuenca-Royo, A; de la Torre, R; de Sola, S; Del Hoyo, L; Dierssen, M; Espadaler, JM; Esteba, S; Farré, M; Gomis-González, M; Hernandez, G; Langohr, K; León, A; Martínez-Leal, R; Milá, M; Novell, R; Ozaita, A; Rodriguez, J; Sánchez-Gutiérrez, J; Xicota, L | 1 |
| De Toma, I; Dierssen, M; Manubens-Gil, L; Ossowski, S | 1 |
1 review(s) available for catechin and Fra(X) Syndrome
| Article | Year |
|---|---|
Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders.
Topics: Antioxidants; Catechin; Cognition; DNA Methylation; Down Syndrome; Epigenesis, Genetic; Fragile X Syndrome; Gene-Environment Interaction; Genetic Therapy; Humans; Intellectual Disability; Protein Interaction Domains and Motifs | 2016 |
1 trial(s) available for catechin and Fra(X) Syndrome
| Article | Year |
|---|---|
A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.
Topics: Adult; Animals; Catechin; Cognition Disorders; Disease Models, Animal; Double-Blind Method; Female; Fragile X Syndrome; Humans; Male; Mice; Mice, Knockout; Middle Aged; Neuroprotective Agents; Treatment Outcome; Young Adult | 2020 |